PRELUDE THERAPEUTICS INC Share-based Payment Arrangement, Expense
PRELUDE THERAPEUTICS INC (PRLD) reported Share-based Payment Arrangement, Expense of $2.03 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AllocatedShareBasedCompensationExpense · last filed 2026-08-11
- PRELUDE THERAPEUTICS INC share-based payment arrangement, expense for the quarter ending 2026-06-30 was $2.03M, a 46.85% decline year-over-year.
- PRELUDE THERAPEUTICS INC share-based payment arrangement, expense for the quarter ending 2026-03-31 was $2.00M, a 47.81% decline year-over-year.
- PRELUDE THERAPEUTICS INC share-based payment arrangement, expense for the quarter ending 2025-12-31 was $1.84M, a 51.14% decline year-over-year.
- PRELUDE THERAPEUTICS INC share-based payment arrangement, expense for the quarter ending 2025-09-30 was $2.42M, a 59.11% decline year-over-year.
- PRELUDE THERAPEUTICS INC share-based payment arrangement, expense for fiscal 2025 was $11.91M, a 44.19% decline from fiscal 2024.
- PRELUDE THERAPEUTICS INC share-based payment arrangement, expense for fiscal 2024 was $21.34M, a 16.67% decline from fiscal 2023.
- PRELUDE THERAPEUTICS INC share-based payment arrangement, expense for fiscal 2023 was $25.62M, a 1.88% increase from fiscal 2022.
- PRELUDE THERAPEUTICS INC share-based payment arrangement, expense for fiscal 2022 was $25.14M, a 20.13% increase from fiscal 2021.
| Period end | Share-based Payment Arrangement, Expense 3 month | Share-based Payment Arrangement, Expense 6 month | Share-based Payment Arrangement, Expense 9 month | Share-based Payment Arrangement, Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.03M 10-Q · filed 2026-08-11 | $4.03M 10-Q · filed 2026-08-11 | $5.87M derived: sum of 3 quarters · filed 2026-08-11 | $8.29M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $2.00M 10-Q · filed 2026-05-12 | $3.84M derived: sum of 2 quarters · filed 2026-05-12 | $6.27M derived: sum of 3 quarters · filed 2026-05-12 | $10.08M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $1.84M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $4.27M derived: sum of 2 quarters · filed 2026-03-10 | $8.08M derived: sum of 3 quarters · filed 2026-08-11 | $11.91M 10-K · filed 2026-03-10 |
| 2025-09-30 | $2.42M 10-Q · filed 2025-11-12 | $6.24M derived: sum of 2 quarters · filed 2026-08-11 | $10.07M 10-Q · filed 2025-11-12 | $13.84M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $3.81M 10-Q · filed 2026-08-11 | $7.65M 10-Q · filed 2026-08-11 | $11.42M derived: sum of 3 quarters · filed 2026-08-11 | $17.35M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $3.83M 10-Q · filed 2026-05-12 | $7.61M derived: sum of 2 quarters · filed 2026-05-12 | $13.53M derived: sum of 3 quarters · filed 2026-05-12 | $19.63M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $3.77M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $9.70M derived: sum of 2 quarters · filed 2026-03-10 | $15.80M derived: sum of 3 quarters · filed 2026-03-10 | $21.34M 10-K · filed 2026-03-10 |
| 2024-09-30 | $5.93M 10-Q · filed 2025-11-12 | $12.02M derived: sum of 2 quarters · filed 2025-11-12 | $17.57M 10-Q · filed 2025-11-12 | $23.48M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $6.10M 10-Q · filed 2025-08-14 | $11.64M 10-Q · filed 2025-08-14 | $17.56M derived: sum of 3 quarters · filed 2025-08-14 | $24.27M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $5.55M 10-Q · filed 2025-05-06 | $11.46M derived: sum of 2 quarters · filed 2025-05-06 | $18.17M derived: sum of 3 quarters · filed 2025-05-06 | $24.91M derived: sum of 4 quarters · filed 2025-05-06 |
| 2023-12-31 | $5.91M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10 | $12.63M derived: sum of 2 quarters · filed 2025-03-10 | $19.36M derived: sum of 3 quarters · filed 2025-03-10 | $25.62M 10-K · filed 2025-03-10 |
| 2023-09-30 | $6.71M 10-Q · filed 2024-11-06 | $13.45M derived: sum of 2 quarters · filed 2024-11-06 | $19.70M 10-Q · filed 2024-11-06 | $25.55M derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | $6.73M 10-Q · filed 2024-08-12 | $12.99M 10-Q · filed 2024-08-12 | $18.83M derived: sum of 3 quarters · filed 2024-08-12 | $25.28M derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | $6.26M 10-Q · filed 2024-05-07 | $12.10M derived: sum of 2 quarters · filed 2024-05-07 | $18.54M derived: sum of 3 quarters · filed 2024-05-07 | $24.57M derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | $5.84M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | $12.29M derived: sum of 2 quarters · filed 2024-02-15 | $18.32M derived: sum of 3 quarters · filed 2024-02-15 | $25.14M 10-K · filed 2024-02-15 |
| 2022-09-30 | $6.44M 10-Q · filed 2023-11-01 | $12.47M derived: sum of 2 quarters · filed 2023-11-01 | $19.30M 10-Q · filed 2023-11-01 | $25.07M derived: sum of 4 quarters · filed 2023-11-01 |
| 2022-06-30 | $6.03M 10-Q · filed 2023-08-03 | $12.86M 10-Q · filed 2023-08-03 | $18.63M derived: sum of 3 quarters · filed 2023-08-03 | $25.66M derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | $6.83M 10-Q · filed 2023-05-08 | $12.60M derived: sum of 2 quarters · filed 2023-05-08 | $19.64M derived: sum of 3 quarters · filed 2023-05-08 | $23.87M derived: sum of 4 quarters · filed 2023-05-08 |
| 2021-12-31 | $5.78M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | $12.81M derived: sum of 2 quarters · filed 2023-03-15 | $17.05M derived: sum of 3 quarters · filed 2023-03-15 | $20.93M 10-K · filed 2023-03-15 |
| 2021-09-30 | $7.03M 10-Q · filed 2022-11-14 | $11.27M derived: sum of 2 quarters · filed 2022-11-14 | $15.16M 10-Q · filed 2022-11-14 | $18.28M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $4.24M 10-Q · filed 2022-08-09 | $8.12M 10-Q · filed 2022-08-09 | $11.24M derived: sum of 3 quarters · filed 2022-08-09 | $12.72M derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | $3.89M 10-Q · filed 2022-05-10 | $7.01M derived: sum of 2 quarters · filed 2022-05-10 | $8.48M derived: sum of 3 quarters · filed 2022-05-10 | $9.11M derived: sum of 4 quarters · filed 2022-05-10 |
| 2020-12-31 | $3.12M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $4.59M derived: sum of 2 quarters · filed 2022-03-17 | $5.22M derived: sum of 3 quarters · filed 2022-03-17 | $5.58M 10-K · filed 2022-03-17 |
| 2020-09-30 | $1.47M 10-Q · filed 2021-11-12 | $2.10M derived: sum of 2 quarters · filed 2021-11-12 | $2.46M 10-Q · filed 2021-11-12 | $2.79M derived: sum of 4 quarters · filed 2021-11-12 |
| 2020-06-30 | $627.00K 10-Q · filed 2021-08-12 | $989.00K 10-Q · filed 2021-08-12 | $1.31M derived: sum of 3 quarters · filed 2021-08-12 | $1.61M derived: sum of 4 quarters · filed 2021-08-12 |
| 2020-03-31 | $362.00K 10-Q · filed 2021-05-11 | $688.00K derived: sum of 2 quarters · filed 2021-05-11 | $985.00K derived: sum of 3 quarters · filed 2021-05-11 | |
| 2019-12-31 | $326.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-16 | $623.00K derived: sum of 2 quarters · filed 2021-03-16 | $846.00K 10-K · filed 2021-03-16 | |
| 2019-09-30 | $297.00K 10-Q · filed 2020-11-10 | $520.00K 10-Q · filed 2020-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |